Evidence map›Paper›PMID 42477299›Full record

ArticleEJNMMI radiopharmacy and chemistry2026

Synthesis and in vitro evaluation of pharmacokinetically optimized

Veronika Felber, Nadine Holzleitner, Thomas Günther

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI radiopharmacy and chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Veronika FelberTUM School of Natural Sciences, Department of Chemistry, Chair of Pharmaceutical Radiochemistry, Technical University of Munich, Walther-Meißner-Str. 3, 85748, Garching, Germany. veronika.felber@univie.ac.at.ORCID http://orcid.org/0000-0003-0072-9769
Nadine HolzleitnerDepartment of Nuclear Medicine, TUM University Hospital and Central Institute for Translational Cancer Research, (TranslaTUM), School of Medicine, Technical University of Munich, Munich, Germany.
Thomas GüntherMolecular Imaging Program at Stanford (MIPS), Department of Radiology, School of Medicine, Stanford University, Stanford, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHitherto, clinically applied

resultsCCK-2R ligands were prepared by solid-phase peptide synthesis (SPPS) and

conclusionsSeveral

Indexed as

CCK-66Cholecystokinin-2 receptorDiagnosisMedullary thyroid carcinomaPeptide receptor radionuclide therapySPECTTechnetium-99 m

Identifiers

PMID42477299
PMCPMC13388586

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.